| Literature DB >> 28448466 |
Paloma Yáñez-Sedeño1, Susana Campuzano2, José M Pingarrón3.
Abstract
Management and prognosis of disease requires the accurate determination of specific biomarkers indicative of normal or disease-related biological processes or responses to therapy. Moreover since multiple determinations of biomarkers have demonstrated to provide more accurate information than individual determinations to assist the clinician in prognosis and diagnosis, the detection of several clinical biomarkers by using the same analytical device hold enormous potential for early detection and personalized therapy and will simplify the diagnosis providing more information in less time. In this field, electrochemical immunosensors have demonstrated to offer interesting alternatives against conventional strategies due to their simplicity, fast response, low cost, high sensitivity and compatibility with multiplexed determination, microfabrication technology and decentralized determinations, features which made them very attractive for integration in point-of-care (POC) devices. Therefore, in this review, the relevance and current challenges of multiplexed determination of clinical biomarkers are briefly introduced, and an overview of the electrochemical immunosensing platforms developed so far for this purpose is given in order to demonstrate the great potential of these methodologies. After highlighting the main features of the selected examples, the unsolved challenges and future directions in this field are also briefly discussed.Entities:
Keywords: biomarkers; cancer; cardiovascular; microfluidic; multiplexed electrochemical immunosensors; paper electrodes
Mesh:
Substances:
Year: 2017 PMID: 28448466 PMCID: PMC5464191 DOI: 10.3390/s17050965
Source DB: PubMed Journal: Sensors (Basel) ISSN: 1424-8220 Impact factor: 3.576
Multiplexed electrochemical immunosensors involving electrode arrays.
| Electrodes | Label | Analyte | Immunoassay | Technique | Linear Range | LOD | Sample | Ref. |
|---|---|---|---|---|---|---|---|---|
| Cancer biomarkers | ||||||||
| GA/Chit/SPAuEs (2WEs) | Strept/AuNPs/CNHs | AFP | Sandwich-type; | LSASV | 0.1–1000 pg·mL−1 | 0.024 pg·mL−1 AFP | serum | [ |
| SPAuEs (4WEs) | AuNRs-HRP | phospho-p53392 | Sandwich-type; detection of H2O2/THI | SWV | 0.01–20 nM p53392 | 5 pM p53392 | plasma | [ |
| carboxylated-SPCEs (16WEs) | HRP-MWCNTs | PSA | Sandwich-type; | amperometry | 5–4000 pg·mL−1 PSA | 5 pg·mL−1 PSA | serum | [ |
| AuNPs film/PDMS (8 × 8 WEs) | HRP/AuNRs | PSA; PSMA; | Sandwich-type; | amperometry | 0.1–10 ng·mL−1 PSA | 0.1 ng·mL−1 PSA | serum | [ |
| G/SPCEs (3WEs) | M-PtNPs | CA125, CA153, CEA | Sandwich-type; | DPV | 0.05–20 U·mL−1 CA125; | 0.002 U·mL−1; | serum | [ |
| Chit/SPCEs (2WEs) | AuNPs | CEA | Sandwich-type; | LSASV | 0.005–5.0 ng·mL−1 | 3.5 pg·mL−1 CEA | serum | [ |
| Chit/SPCEs | Strept/AgNPs/MWCNTs | CEA | Sandwich-type; | LSASV | 0.1–5000 pg·mL−1 | 0.093 pg·mL−1 CEA | serum | [ |
| AuNPs/G/SPCEs (3WEs) | AP-AuCs/G | CA153, CA125, CEA | Sandwich-type; addition of 3-IP and Ag deposition | LSASV | 0.005–50 U·mL−1 CA 153 | 0.0015 U·mL−1 CA 153 | serum | [ |
| SPCEs (2WEs) | Strept-HRP | ERα | Sandwich-type magnetoimmuno-sensor; detection of H2O2/HQ | amperometry | 73–1500 pg·mL−1 (PR) | 22 pg·mL−1 (PR) | cell lysates | [ |
| Cardiac biomarkers | ||||||||
| CNF microE chip (3 × 3) | - | CRP, cTNI, Mb | Direct; detection of Fe(CN)64− | DPV | - | - | serum | [ |
| HOOC-MBs/SPCEs (2WEs) | HRP | NT-proBNP CRP | Competitive ( NT-pro BNP); sandwich-type (CRP); detection of H2O2 in presence of TMB | amperometry | 2.5–504 ng·mL−1 NT-proBNP | 0.47 ng·mL−1 | serum | [ |
| SiNW array | - | cTnT, CK-MM, CK-MB | Direct assay | Resistance changes caused by specific binding | 1 pg·mL−1–10 ng·mL−1 | 1 pg·mL−1 (2 μL blood 45 min) | blood | [ |
| Other clinical biomarkers | ||||||||
| HOOC-Phe-DWCNTs/SPCEs (2WEs) | poly-HRP-Strept | IL-1β | Sandwich-type; | amperometry | 0.5–100 pg·mL−1 IL-1β | 0.38 pg·mL−1 IL-1β | serum | [ |
| Au microE chip (8WEs) | - | IL-1β, IL-10, IL-6 | Direct; detection of Fe(CN)63−/4− | EIS | 1–15 pg·mL−1 | - | - | [ |
| rGO/SPCEs (2WEs) | Strept-AP | GHRL | Sandwich-type; addition of 1-NPP | DPV | 10−3–100 ng·mL−1 GHRL | 1.0 pg·mL−1 GHRL | serum saliva | [ |
| SPCEs (2WEs) | Strept-AP | cortisol | Sandwich-type; addition of 1-NPP | DPV | 0.1–500 ng·mL−1 cortisol | 37 pg·mL−1 cortisol | serum | [ |
| AuNPs/MWCNTs/SPCEs (2WEs) | AP | IgA and IgG type AGA | Sandwich-type; addition of 3-IP and Ag deposition | cyclic-ASV | up to 100 U mL−1 | 2.45 U·mL−1 tTG IgA | serum | [ |
Abbreviations: AFP, alpha fetoprotein; AP, alkaline phosphatase; AuNRs, gold nanorods; BSA, bovine serum albumin; CA125, CA153, carbohydrate antigen 123 or 153; CEA, carcinoembryonic antigen; Chit, chitosan; CNF, carbon nanofiber; DPV, differential pulse voltammetry; EIS, electrochemical impedance spectrospocy; ERα, estrogen receptor α; G, graphene; GA, glutaraldehyde; GHRL, ghrelin; hCG, human chorionic gonadotropin; HRP, horse-raddish peroxidase; IL, interleukin; 3-IP, 3-indoxyl phosphate; ITO, indium tin oxide electrode; LSASV, linear sweep-anodinc stripping voltammetry; MPtNPs, mesoporous platinum nanoparticles; 1-NPP, 1-naphthylphosphate; PB, Prussian blue; PDMS, polydimethylsiloxane; PSA, prostate specific antigen; PSMA, prospate specific membrane antigen; PWE, paper working electrode; PYY, peptide YY; rGO, reduced graphene oxide; SPAuEs, screen-printed gold electrodes; SPCEs, screen-printed carbon electrodes; Strept, streptavidin; TB, toluidine blue; TCCRMSs, tryptophan and caffeic acid-based resin; THI, thionine;.TMB, 3,3’,5,5’-tetramethylbenzidine; TNF-α, tumor necrosis factor alfa; WE, working electrode; ZNRs, zinc oxide nanorods.
Multiplexed electrochemical immunosensors using barcode configurations.
| Electrode | Label | Analyte | Immunoassay | Technique | Linear Range | LOD | Sample | Ref. |
|---|---|---|---|---|---|---|---|---|
| Cancer biomarkers | ||||||||
| G/Au/GCE | THI (or Co or Fc or AQ)-Strept-Biotin-dsDNA/Strept-Biotin-Ab2/AuNPs/SiO2/Fe3O4 | CEA, CA125, PSA, AFP | Sandwich-type; direct detection after conjugation | DPV | 0.2–600 pg·mL−1 CEA; | 48 fg·mL−1 CEA; | - | [ |
| AuNPs/GCE | PVP/GS/PtPdNPs/HRP/AQ PVP/GS/PtPdNPs/HRP/THI | AFP, APT; DCP, AFP-L3, γ-GT, AFU | Sandwich-type; addition of H2O2 | DPV | 0.025–5.0 ng·mL−1 AFP; | 0.008 ng·mL−1 AFP; | serum | [ |
| GCE (Hg) | PAMAM-CdS (or ZnS, or PbS) | CA125 | Sandwich-type; direct detection of Cd, Zn and Ag | SWASV | 0.01–50 U·mL−1 | 0.005 U·mL−1 | serum | [ |
| IL/rGO/GCE | PtNPs-Cu2+ | AFP | Sandwich-type; reduction of metal ions | DPV | 0.05–200 ng·mL−1 | 0.05 ng·mL−1 AFP | serum | [ |
| AuNPs/Chit/GCE | CGS-PB; | CEA; AFP | Sandwich-type; direct detection | DPV | 0.5–60 ng·mL−1 | 0.1 ng·mL−1 (CEA) | serum | [ |
| AuNPs/Chit/GCE | Chit/AuNPs/PB; | CEA; AFP | Sandwich-type; direct detection | DPV | 0.05–100 ng·mL−1 | 0.02 ng·mL−1 (CEA) | serum | [ |
| HAG/PANI/rGO/GCE | AuNPs/rGO/PB; AuNPs/rGO/PDDA/THI | CEA; AFP | Sandwich-type; direct detection | DPV | 0.6–80 ng·mL−1 | 0.12 ng·mL−1 (CEA) | serum | [ |
| AuNPs/GCE | Fc/HRP | CEA | Direct assay after addition of H2O2 | DPV | 0.01–50 ng·mL−1 | 0.01 ng·mL−1 | serum | [ |
| AuNPs/G/GCE | THI-HRP-NPG-MnO2 | CA-15-3 | Sandwich-type; addition of H2O2 | SWV | 0.01–50 U·mL−1 | 3.5 mU·mL−1 (CA-153) | serum | [ |
| PDPMT-Cl-Chit/GCE | THI-Fe3O4NPs | SCC-Ag | Sandwich; direct detection | DPV | 0.01–10 ng·mL−1 | 4 pg·mL−1 (SCC-Ag) | serum | [ |
| CD/G/GCE | CD/Fc/G | CEA | Sandwich-type with HRP-Ab2 and H2O2 detection | DPV | 0.003–40 ng·mL−1 CEA | 0.8 pg·mL−1 CEA | serum | [ |
| rGO/THI (or PB)/AuNPs/ITO | - | CEA | Direct detection of of THI or PB | SWV | 0.01–300 ng·mL−1 | 0.650 pg·mL−1 CEA | serum | [ |
| TB (orPB)/AuNPs/TCCRMSs/FTO | - | CEA | Direct; detection of TB or PB | SWV | 2–25 ng·mL−1 | 0.11 ng·mL−1 CEA | serum | [ |
| HOOC-MBs/SPCE | ACTP/AuNPs | p5315, p53392 | Sandwich-type; | SWV | 1–20 ng·mL−1 (p5315) | 0.5 ng·mL−1 (p5315) | serum | [ |
| GCE (Bi) | G/AuNPs-r-Apo-Cd | AFP | Sandwich-type; detection of metals | SWASV | 0.001–5 ng·mL−1 | 0.3 pg·mL−1 AFP; | serum | [ |
| rGO | CdSeTe@CdS | Bcl-2 | Sandwich-type; direct detection of Cd and Ag | SWASV | 1–250 ng·mL−1 | 0.5 fmol | leukemiaK562 cells | [ |
| Chit/MWCNTs/GCE | OMC-Zn | AFP | Sandwich-type; oxidation of metal ions | DPV | 0.001–150 ng·mL−1 | 0.6 pg·mL−1 AFP | serum | [ |
| GCE | EnvisionTM-CdS (or PbS or AuNPs) | AFP | Sandwich-type; detection of metals | DPASV | 0.001–50 ng·mL−1 AFP; CEA; | 0.02 pg·mL−1 AFP; | serum | [ |
| Glu/Chit/AuNPs/AuE | BSA/AuNPs-Pb2+ | CEA | Sandwich-type; reduction of metal ions | DPV | 0.01–50 ng·mL−1 | 4.6 pg·mL−1 CEA | serum | [ |
| AuNPs/AuE | AuNPs@MWCNTs-Pb2+ | CEA | Sandwich-type; reduction of metal ions | SWV | 0.01–60 ng·mL−1 | 3.0 pg·mL−1 CEA | serum | [ |
| AuNPs/rGO/Chit | AgNPs/THI/CNSs | CEA | Sandwich-type; direct detection | DPV | 0.01–80 ng·mL−1 | 2.8 pg·mL−1 CEA | serum | [ |
| IL/rGO/PSS/GCE | CGN-THI CGN-DAP CGN-Cd2+ | CEA | Sandwich-type; direct detection | SWV | 0.01–100 ng·mL−1 | 2.7 pg·mL−1 CEA | serum | [ |
| AuNPs/AuE | TiO2/Nf- Co(dcbpy)32+ | CA15-3 | Sandwich-type; direct detection | DPV | 5–100 U·mL−1 CA15-3 | 0.3 UmL−1 CA15-3 | serum | [ |
| AuNPs/PAPT/GCE | poly(VFc-ATP) | AFP | Sandwich-type; direct detection | DPV | 0.01–100 ng·mL−1 | 0.003 ng·mL−1 AFP | serum | [ |
| AuNPs/G/GCE | PS-Cd2+ | IL-6 | Sandwich-type; direct detection | SWV | 1–1000 pg·mL−1 IL-6 | 0.5 pg·mL−1 | serum | [ |
| Protein A/Nafion/GCE | GS/AuNPs-THI | AFP | Sandwich.type; | DPV | 0.016–50 ng·mL−1 AFP | 5.4 pg·mL−1 AFP | - | [ |
| AuNPs/PEI/PTCA/GCE | Au@PBNPs/O-GS-Strept-AP; Au@NiNPs/O-GS-Strept-AP | fPSA | Sandwich-type; AA-P addition | DPV | 0.02–10 ng·mL−1 fPSA | 6.7 pg·mL−1 | serum | [ |
| MWCNTs/GCE | AA liposome | NSE | Sandwich-type, direct detection | LSV | 50–1000 pg·mL−1 | 5.0 pg·mL−1 NSE | serum | [ |
| AuNPs/IL/rGO/GCE | Cd (or Pb or Cu) AlgNBs | AFP | Sandwich-type; | DPV | 0.01–100 ng·mL−1 | 0.01 ng·mL−1AFP | serum | [ |
| GCE (Bi) | PLL/AuNPs/Cd-Apo (or Pb-Apo) | AFP | Sandwich-type; | ASSWV | 0.01–50 ng·mL−1 | 4 pg·mL−1 | serum | [ |
| Chit/AuNPs/GCE | GA/Chit/pAA NSs-Cu2+ (or Cd2+ or Zn2+) | CEA | Sandwich-type; | SWV | 0.1–100 ng·mL−1 CEA | 0.02 ng·mL−1 CEA | serum | [ |
Abbreviations: AA, ascorbic acid; AA-P, ascorbic acid 2-phosphate; ACTP, apoferritin templated cadmium phosphates; AFP, alpha fetoprotein; AFP-L3, lens culinaris (LCA)-reactive fraction of AFP; AFU, alpha-L-fucosidase; AgNCs, silver nanoclusters; Alg, alginate; Apo, apoferritin; APT, abnormal prothrombin; ATLP, apoferritin templated lead phosphates; AU, uric acid; Bax, Bcl-2 associated X protein; Bcl, B-cell lymphoma; CEA, Chit, chitosan; CGN, carbon-gold nanocomposite; CGS, carboxyl graphene nanosheet; CNS, carbon nanospheres; DCP, des-c-carboxy prothrombin; Fc. ferrocene; fPSA, free-prostate specific antigen; FTO, fluorine-doped tin oxide; G, graphene; γ-GT, γ-glutamyltranspeptidase; GCE, glassy carbon electrode; O-GS, onion-like graphene sheet; HER-2, human epidermal growth factor receptor type-2; HRP, horse-raddish peroxidase; IL, ionic liquid; NPG, nanoporous gold; NSE, neuron-specific enolase; OMC, ordered mesoporous carbon; pAA, polyacrylic acid; PATP, poly(2-aminothiophenol); PB, Prussian blue; PDPMT-Cl, poly(3-(1,1-o-dimethyl-4-piperidine-methylene)thiophene-2,5-diylchloride); PEI, polyethyleneimine; PLL, poly-L-lysine; POPD, poly(o-phenylenediamine); ProGRP, pro-gastrin-releasing peptide; PTCA, 3,4,9,10-perylenetetracarboxylic acid; SS2, streptococcus suis serotype 2; TB, toluidine blue; TCCMRSs, tryptophan and caffeic acid-based resin microspheres; TB, toluidine blue; THI, thionine; UA, uric acid; VFc-ATP, vinyl ferrocene-2-aminothiophenol.
Figure 1Multiplexed electrochemical immunoplatform for the simultaneous determination of phosphorylated p53 at Ser392 (phospho-p53392), Ser15 (phospho-p5315), Ser46 (phospho-p5346), and total p53 using electric field-driving and multi-enzyme labeling amplification. Reprinted from Ref. [8] with permission.
Figure 2Scheme of the preparation and functioning of a multiplexed immunosensor for the determination of CEA and AFP involving stripping voltammetry of Ag catalytically deposited by gold nanolabels. Reprinted from Ref. [21] with permission.
Figure 3Schematic display of the disposable dual magnetoimmunosensor prepared for the determination of NT-proBNP and CRP. Reprinted from Ref. [26] with permission.
Figure 4Scheme of the different steps involved in the preparation and functioning of the dual GHRL and PYY immunosensors. Reprinted from Ref. [30] with permission.
Figure 5Schematic illustration of the fundamentals for the preparation of a sandwich-type immunosensor for the simultaneous detection of four cancer biomarkers, CEA, AFP, CA125 and PSA. Inset shows an example of the DPV recorded voltammogram. Modified from Ref. [6] with permission.
Figure 6Schematic illustration of the fabrication procedure of the immunosensor developed for CA15-3 and CA125 using NPG-MnO2 and THI or Fc as the redox probes. (A) Functionalization of NPG with cactus-like MnO2; (B) Steps involved in the preparation of the immunosensor. Reprinted from Ref. [37] with permission.
Figure 7Preparation of HRP/PtPd/GS labeled redox probe branched antibodies (A). (B) Stepwise immunosensor fabrication process and DPV electrochemical responses. Reprinted from Ref. [12] with permission.
Figure 8Scheme of the multiplexed electrochemical immunosensor for the simultaneous determination of AFP and CEA. Preparation of signal tags (A); preparation of MMIP and capture of AFP and CEA antigens followed by immunocomplexation and electrochemical detection (B). Reprinted from [43] with permission.
Figure 9Multiplexed stripping voltammetric immunoassay using dendrimer-metal sulfide QD nanolabels (DE-QD) and tri-functionalized magnetic beads for the simultaneous determination of CA125, CA15-3 and CA19-9 cancer biomarkers: (a) preparation process and (b) measurement principle. Reprinted from [13] with permission.
Figure 10Multiplexed electrochemical immunosensors for detection of CEA and AFP using CNSs coated with AgNPs or AuNPs and THI for immobilization of secondary antibodies. Preparation of immunoprobes (A). Immunosensor fabrication procedure and recorded voltammetric signals (B). Reprinted from [49] with permission.
Figure 11(A) Scheme of the electrochemical immunosensor constructed for the simultaneous determination of IL-6 and IL-17 using two different tags to polystyrene spheres and Cd2+ and Fc as the electroactive labels. (B) SW voltammograms recorded for the simultaneous detection of (a–e) 5, 50, 100, 500 and 1000 pg·mL−1 IL-6 (left) and IL-17 (right). Repinted from Ref. [53] with permission.
Figure 12Scheme of the multiplexed electrochemical immunoassay for CEA and AFP using magnetic graphene nanosheets with immobilized capture antibodies as immunosensing probes, and multifunctional nanogold hollow microspheres (GHS) with encapsulated HRP-THI and HRP-Fc as distinguishable signal tags. Figure shows also some of the voltammograms recorded. Reprinted from Ref. [17] with permission.
Figure 13Fabrication process of the paper electrode-based immunosensor exemplified for one analyte. Reprinted from Ref. [100] with permission.